Science

Publications

2023

  • . Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Current Phase 1 (P1) results.

    PCF 2023 Poster Presentation

  • . Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Current Phase 1 (P1) results. ESMO Virtual Congress 2023.

    ESMO 2023 Poster Presentation

  • Lacetti, Andrew et al. Phase 1/2 Trial of Oral EPI-7386 in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Preliminary Results from the Phase 1 (P1) Dose-optimization Component of the Study. 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium.

    ASCO GU 2023 Poster Presentation

  • Pachynski, Russel et al. A Phase 1 Trial of Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Update From the First-in-Human Study. 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

    ASCO GU 2023 Poster Presentation

2022

  • Hong, NH. et al. Advances in the Development of a Targeted N-Terminal Domain Androgen Receptor Degrader (ANITAC) for the Treatment of Prostate Cancer. 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

    EORTC-NCI-AACR 2022 Poster Presentation